| Acronym/Abbreviation | Name |
| ACTG | AIDS Clinical Trials Group |
| ADVANCE | Assessing Donor Variability And New Concepts in Eligibility |
| ARDENT | ACTG A5257 trial |
| ARTEMIS | Affordability and Real-world Antiplatelet Treatment Effectiveness After Myocardial Infarction Study |
| ATLAS | Antiretroviral Therapy as Long-Acting Suppression |
| D:A:D | Data Collection on Adverse Events of Anti-HIV Drugs |
| ECHO | Evidence for Contraceptive Options in HIV |
| ENCORE | Evaluation of Novel Concepts in Optimization of antiRetroviral Efficacy |
| FLAIR | First Long-Acting Injectable Regimen |
| FLAMINGO | Dolutegravir Compared to Darunavir/Ritonavir, Each in Combination With Dual Nucleoside ReverseTranscriptase Inhibitors |
| HPTN | HIV Prevention Trials Network |
| NADIA | Nucleosides And Darunavir/Dolutegravir In Africa |
| NAMSAL | New Antiretroviral and Monitoring Strategies in HIV-infected Adults in Low-Income Countries |
| STaR | Single-Tablet Regimen |
| START | Strategic Timing of AntiRetroviral Trea |
Menu
